EA013367B1 - Соли и полиморфные формы эффективного антидиабетического соединения - Google Patents

Соли и полиморфные формы эффективного антидиабетического соединения Download PDF

Info

Publication number
EA013367B1
EA013367B1 EA200600701A EA200600701A EA013367B1 EA 013367 B1 EA013367 B1 EA 013367B1 EA 200600701 A EA200600701 A EA 200600701A EA 200600701 A EA200600701 A EA 200600701A EA 013367 B1 EA013367 B1 EA 013367B1
Authority
EA
Eurasian Patent Office
Prior art keywords
compound
polymorphic form
receptor
ρρακ
salts
Prior art date
Application number
EA200600701A
Other languages
English (en)
Russian (ru)
Other versions
EA200600701A1 (ru
Inventor
Генри Т. Крак
Лоренс Р. Маги
Бин ЯН
Original Assignee
Эмджен Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эмджен Инк. filed Critical Эмджен Инк.
Publication of EA200600701A1 publication Critical patent/EA200600701A1/ru
Publication of EA013367B1 publication Critical patent/EA013367B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EA200600701A 2003-10-03 2004-10-04 Соли и полиморфные формы эффективного антидиабетического соединения EA013367B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50847003P 2003-10-03 2003-10-03
PCT/US2004/032552 WO2005033074A2 (en) 2003-10-03 2004-10-04 Salts and polymorphs of a potent antidiabetic compound

Publications (2)

Publication Number Publication Date
EA200600701A1 EA200600701A1 (ru) 2006-10-27
EA013367B1 true EA013367B1 (ru) 2010-04-30

Family

ID=34421741

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200600701A EA013367B1 (ru) 2003-10-03 2004-10-04 Соли и полиморфные формы эффективного антидиабетического соединения

Country Status (19)

Country Link
US (2) US7223761B2 (ja)
EP (1) EP1677797B1 (ja)
JP (2) JP5426813B2 (ja)
KR (1) KR101156277B1 (ja)
CN (1) CN1886134A (ja)
AT (1) ATE546142T1 (ja)
AU (1) AU2004278416B2 (ja)
BR (1) BRPI0414957A (ja)
CA (1) CA2540536C (ja)
DK (1) DK1677797T3 (ja)
EA (1) EA013367B1 (ja)
ES (1) ES2386670T3 (ja)
IL (1) IL174728A (ja)
IS (1) IS8378A (ja)
MX (1) MXPA06003313A (ja)
NO (1) NO333002B1 (ja)
NZ (1) NZ546783A (ja)
WO (1) WO2005033074A2 (ja)
ZA (1) ZA200602669B (ja)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041691B1 (en) * 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
US6653332B2 (en) 2000-05-03 2003-11-25 Tularik Inc. Combination therapeutic compositions and method of use
US20030171399A1 (en) * 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
US7223761B2 (en) * 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
BRPI0620268B8 (pt) * 2005-12-22 2021-05-25 Oakwood Laboratories LLC composição eficaz como sistema de fornecimento para liberação controlada, seu uso, seu método de fabricação, e método para proteger um agente biologicamente ativo
DE602007012299D1 (de) * 2006-09-21 2011-03-10 Piramal Live Science Ltd Pyridinderivate für die behandlung von stoffwechselstörungen, die mit insulinresistenz oder hyperglykämie in zusammenhang stehen
WO2009111078A2 (en) * 2008-03-06 2009-09-11 Intekrin Therapeutics, Inc. Combination of a ppary agonist and a dipeptidyl peptidase-inhibitor for the treatment of diabetes and obesity
US20100087481A1 (en) * 2008-10-03 2010-04-08 Lee Kathleen M Oral pharmaceutical formulations for antidiabetic compounds
WO2011017488A2 (en) * 2009-08-05 2011-02-10 Intekrin Therapeutics, Inc. Combination of a selective ppar-gamma modulator and an incretin for the treatment of diabetes and obesity
BR112013007469B1 (pt) * 2010-09-21 2020-03-31 Intekrin Therapeutics, Inc. Composições farmacêuticas antidiabéticas sólidas, seu uso e método de preparação, método para preparar um produto de granulação e composição precursora farmacêutica
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
SG11201505944QA (en) * 2013-01-30 2015-08-28 Intekrin Therapeutics Inc PPARγ AGONISTS FOR TREATMENT OF MULTIPLE SCLEROSIS
EA201791982A1 (ru) 2015-03-09 2020-02-17 Интекрин Терапьютикс, Инк. Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
WO2017178408A1 (en) 2016-04-15 2017-10-19 Syngenta Participations Ag Microbiocidal silicon containing aryl derivatives
WO2018035446A1 (en) * 2016-08-18 2018-02-22 Intekrin Therapeutics, Inc. PPARγ AGONIST FOR TREATMENT OF BLOOD CANCERS
CN109843292A (zh) * 2016-08-18 2019-06-04 因特克林治疗股份有限公司 治疗骨疾病的PPARγ激动剂
WO2018053040A1 (en) * 2016-09-13 2018-03-22 Intekrin Therapeutics, Inc. Treatment of multiple sclerosis with chs-131
WO2018136635A1 (en) * 2017-01-18 2018-07-26 Coherus Biosciences, Inc. Pparϒ agonist for the treatment of huntington's disease
CA3058806A1 (en) 2017-04-03 2018-10-11 Coherus Biosciences Inc. Ppar.gamma. agonist for treatment of progressive supranuclear palsy
CN109651208B (zh) * 2017-10-10 2022-01-04 中国科学院上海药物研究所 N-芳基磺酰胺类化合物，其药物组合物及其用途
JP2022516509A (ja) 2018-12-31 2022-02-28 コヒラス・バイオサイエンシズ・インコーポレイテッド 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）を治療するための組成物および方法
EP3946336A1 (en) 2019-04-02 2022-02-09 Coherus Biosciences, Inc. Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
WO2020205024A1 (en) 2019-04-04 2020-10-08 Coherus Biosciences, Inc. Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
US20220193065A1 (en) 2019-04-04 2022-06-23 Coherus Biosciences, Inc. Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
WO2020205023A1 (en) 2019-04-04 2020-10-08 Coherus Biosciences, Inc. Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
EP3946335A1 (en) 2019-04-04 2022-02-09 Coherus Biosciences, Inc. Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
US20220202804A1 (en) 2019-05-30 2022-06-30 Coherus Biosciences, Inc. Compositions and methods to treat cancer
US20240066020A1 (en) 2019-10-15 2024-02-29 Coherus Biosciences, Inc. Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
WO2022051318A1 (en) 2020-09-03 2022-03-10 Coherus Biosciences, Inc. Fixed dose combinations of chs-131 and a thyroid receptor beta agonist
WO2022051316A1 (en) 2020-09-03 2022-03-10 Coherus Biosciences, Inc. Fixed dose combinations of chs-131 and a sglt-2 inhibitor
WO2022051319A1 (en) 2020-09-03 2022-03-10 Coherus Biosciences, Inc. Fixed dose combinations of chs-131 and a dpp-4 inhibitor
WO2022051323A1 (en) 2020-09-03 2022-03-10 Coherus Biosciences, Inc. Fixed dose combinations of chs-131 and a ppar agonist
WO2022051321A1 (en) 2020-09-03 2022-03-10 Coherus Biosciences, Inc. Fixed dose combinations of chs-131 and a fxr agonist
JP2022104747A (ja) * 2020-12-29 2022-07-11 国立研究開発法人国立がん研究センター 抗ウイルス剤

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200995B1 (en) * 1998-01-29 2001-03-13 Tularik Inc. PPAR-γ modulators
WO2002000633A1 (en) * 2000-06-28 2002-01-03 Tularik Inc. Quinolinyl and benzothiazolyl ppar-gamma modulators
US6583157B2 (en) * 1998-01-29 2003-06-24 Tularik Inc. Quinolinyl and benzothiazolyl modulators
US6653332B2 (en) * 2000-05-03 2003-11-25 Tularik Inc. Combination therapeutic compositions and method of use
US6770648B2 (en) * 1999-06-30 2004-08-03 Tularik Inc. Compounds for the modulation of PPARγ activity

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2407309A (en) 1942-02-04 1946-09-10 Squibb & Sons Inc Chemotherapeutic agents of the sulphonamide type
CH361275A (de) * 1957-09-10 1962-04-15 Geigy Ag J R Verfahren zur Herstellung von neuen Arylsulfonarylamiden
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
NL138933B (nl) 1969-03-26 1973-05-15 Erba Carlo Spa Werkwijze voor het bereiden van benzeensulfonylureumderivaten met bloedsuikerspiegelverlagende werking.
US3700773A (en) 1969-06-25 1972-10-24 Merck & Co Inc Substituted phenylsulfamyl salicyclic acids and derivatives thereof in the treatment of inflammation
US3686192A (en) 1971-01-04 1972-08-22 Minnesota Mining & Mfg Substituted pyridine derivatives
US4061642A (en) 1972-06-22 1977-12-06 Cassella Farbwerke Mainkur Ag 2,4,6-Trisubstituted-3-pyridine carboxamides
US4062950A (en) 1973-09-22 1977-12-13 Bayer Aktiengesellschaft Amino sugar derivatives
US4003734A (en) 1974-01-22 1977-01-18 The Dow Chemical Company Substituted pyridinyloxy(thio)phenyl-acetamides, -ureas and urea derivatives and herbicidal compositions and methods containing said compounds
CH592411A5 (en) 1974-04-18 1977-10-31 Ciba Geigy Ag Phenoxymethyl- and phenylthiomethyl-pyridine derivs - with insecticidal, acaricidal and plant-growth regulating activity
US4013621A (en) 1975-04-29 1977-03-22 Ciba-Geigy Corporation Substituted sulfonamide derivatives of hindered phenols and stabilized compositions
GB2009146B (en) 1977-11-29 1982-03-24 Ishihara Sangyo Kaisha Sulphonanilide copmouds and herbicidal compositions therof
US4289876A (en) 1978-11-24 1981-09-15 Bristol-Myers Company Antisecretory agents
JPS5579369A (en) 1978-12-13 1980-06-14 Ishihara Sangyo Kaisha Ltd Urea compound, its preparation, and insecticide comprising it
US4499304A (en) 1981-07-06 1985-02-12 Eastman Kodak Company Color-forming sulfonamidodiphenylamines and corresponding sulfonimide dyes
DE3264551D1 (en) 1981-07-06 1985-08-08 Eastman Kodak Co Color-forming sulfonamidodiphenylamines, photographic elements containing them and corresponding sulfonimide dyes
US4577028A (en) 1981-10-20 1986-03-18 Ciba-Geigy Corporation 5-Haloalkyl-pyridines
US4565568A (en) 1982-06-18 1986-01-21 The Dow Chemical Company Pyridyl(oxy/thio)phenoxy compounds, herbicidal compositions and methods
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4731090A (en) 1983-12-23 1988-03-15 Ciba-Geigy Corporation Process for protecting keratinous material from attack by insects feed on keratin with pyridyloxytrifluoromethanesulfonanilides
US4549901A (en) 1984-02-16 1985-10-29 Stauffer Chemical Company 2-[4-(Substituted aryl)phenoxy]-N-substituted-phenylsulfonyl propionamides having herbicidal properties
US4851419A (en) 1985-10-16 1989-07-25 Fisons Plc Certain 2-pyridinyl-phenylsulfinyl-benzoxazoles, the corresponding benzothiazoles or benzimidazoles having anti-inflammatory or gastric acid secretion inhibition activity
DE3545570A1 (de) 1985-12-21 1987-06-25 Hoechst Ag Neue pyridin-derivate und deren n-oxide, verfahren zu ihrer herstellung und ihre verwendung als zwischenprodukte
US4866079A (en) 1986-03-19 1989-09-12 Ciba-Geigy Corporation N-pyridyloxyphenylisothioureas and the use thereof in pest control
DE3632329A1 (de) 1986-09-24 1988-03-31 Bayer Ag Substituierte phenylsulfonamide
US5202336A (en) 1986-09-24 1993-04-13 Bayer Aktiengesellschaft Antiflammatory quinolin methoxy phenylsulphonamides
EP0283504A1 (en) 1986-09-27 1988-09-28 FISONS plc Compounds
JPS646245A (en) 1987-02-20 1989-01-10 Sumitomo Chemical Co Benzylamine derivative, production thereof and germicide containing said derivative as active ingredient
US4670045A (en) 1987-04-07 1987-06-02 The Dow Chemical Company Fungicidal control employing ester derivatives of 4,6-disubstituted 2-pyridinols
GB8724252D0 (en) 1987-10-15 1987-11-18 Ici Plc Fungicides
JPS646245U (ja) 1987-06-30 1989-01-13
JPH01156953A (ja) 1987-09-01 1989-06-20 Hokko Chem Ind Co Ltd ベンゼンスルホンアニリド誘導体および農園芸用殺菌剤
EP0320448B1 (de) 1987-12-07 1994-12-28 Ciba-Geigy Ag 3-Aminobenzoylphenylharnstoffe
DE3823318A1 (de) 1988-07-09 1990-02-22 Bayer Ag (hetero)aryloxynaphthaline mit ueber schwefel gebundenen substituenten
GB8820115D0 (en) 1988-08-24 1988-09-28 Ici Plc Insecticidal compounds
DE3905075A1 (de) 1989-02-18 1990-08-30 Hoechst Ag Benzolsulfonamide und verfahren zu ihrer herstellung
ZA913760B (en) 1990-05-24 1992-02-26 Sumitomo Chemical Co Pyridine derivatives,their production processes and their compounds for control of insect pests
GB9015658D0 (en) 1990-07-17 1990-09-05 Shell Int Research Herbicidal compounds
EP0472053B1 (en) 1990-08-20 1998-06-17 Eisai Co., Ltd. Sulfonamide derivatives
NZ239846A (en) 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
JP3188286B2 (ja) 1991-08-20 2001-07-16 塩野義製薬株式会社 フェニルメトキシイミノ化合物およびそれを用いる農業用殺菌剤
US5204354A (en) 1992-02-14 1993-04-20 Merck & Co., Inc. Substituted quinazolinones as neurotensin antagonists useful in the treatment of CNS disorders
US5514696A (en) 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
JPH06199047A (ja) 1993-01-08 1994-07-19 New Oji Paper Co Ltd 感熱記録体
US5643914A (en) 1993-03-02 1997-07-01 Smithkline Beecham Corporation Pharmaceutical pyridine compounds
EP0706508A1 (en) 1993-06-30 1996-04-17 The Wellcome Foundation Limited Anti-atherosclerotic diaryl compounds
RU2128644C1 (ru) 1993-12-27 1999-04-10 Эйсай Ко., Лтд. Производные антраниловой кислоты или их фармакологически приемлемые соли, промежуточные продукты для их получения и лекарственный препарат на их основе
US5545669A (en) 1994-06-02 1996-08-13 Adams; Jerry L. Anti-inflammatory compounds
US5684195A (en) 1994-07-14 1997-11-04 G. D. Searle & Co. Method of preparing sulfmonamides from sulfones
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (ja) 1994-11-12 1997-12-01 Zeneca Ltd
DE19502753A1 (de) * 1995-01-23 1996-07-25 Schering Ag Neue 9H-Pyrido[3,4-b]indol-Derivate
US5780483A (en) 1995-02-17 1998-07-14 Smithkline Beecham Corporation IL-8 receptor antagonists
US5814646A (en) 1995-03-02 1998-09-29 Eli Lilly And Company Inhibitors of amyloid beta-protein production
US5624937A (en) 1995-03-02 1997-04-29 Eli Lilly And Company Chemical compounds as inhibitors of amyloid beta protein production
US6022897A (en) 1995-04-25 2000-02-08 The Salk Institute For Biological Studies Selective modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof
US5939442A (en) 1995-06-07 1999-08-17 The Salk Institute For Biological Studies Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
EP0778267A4 (en) 1995-06-21 2000-04-05 Otsuka Kagaku Kk SULFONAMIDE DERIVATIVES INCLUDING INSECTICIDES, MITICIDES AND NEMATICIDES
AU7074496A (en) 1995-09-18 1997-04-09 Ligand Pharmaceuticals Incorporated Ppar gamma antagonists for treating obesity
EP1334719A3 (en) 1996-02-22 2003-09-24 Tularik, Inc. Pentafluorobenzenesulfonamides and analogs
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
JPH09255656A (ja) 1996-03-28 1997-09-30 Hiroyoshi Hidaka スルフォンアミド誘導体及びこれを含有する医薬
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
US6294559B1 (en) 1996-05-02 2001-09-25 Merck & Co., Inc. Antiproliferative agents associated with peroxisome proliferator activated receptors gamma1 and gamma2
PL331154A1 (en) 1996-07-13 1999-06-21 Glaxo Group Ltd Bicyclic heteroaromatic compounds as inhibitors of proteinous tyrosine kinase
JP3243733B2 (ja) 1996-08-07 2002-01-07 雪印乳業株式会社 新規イソキノリン誘導体
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
SI0966436T1 (en) 1997-02-21 2003-04-30 Bayer Aktiengesellschaft Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases
DE69809827D1 (de) 1997-03-31 2003-01-16 Korea Res Inst Chem Tech Chinolinische Sulfid-Derivate als NMDA Rezeptor-Antagonisten und Verfahren zu ihrer Herstellung
PH11998001072B1 (en) 1997-05-07 2006-11-21 Univ Pittsburgh Inhibitors of protein isoprenyl transferases
US5981586A (en) * 1997-05-23 1999-11-09 Pershadsingh; Harrihar A. Methods for treating proliferative and inflammatory skin diseases
KR20010014183A (ko) 1997-06-27 2001-02-26 Fujisawa Pharmaceutical Co 술폰아미드 화합물 및 그의 의약 용도
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
FR2773075B1 (fr) * 1997-12-31 2000-05-05 Cird Galderma Utilisation d'activateurs de ppar-gamma en dermatologie
JP4327915B2 (ja) 1998-03-30 2009-09-09 株式会社デ・ウエスタン・セラピテクス研究所 スルフォンアミド誘導体
DE19837627A1 (de) 1998-08-19 2000-02-24 Bayer Ag Neue Aminosäureester von Arylsulfonamiden und Analoga
HN1998000027A (es) 1998-08-19 1999-06-02 Bayer Ip Gmbh Arilsulfonamidas y analagos
US6586475B1 (en) 1998-11-20 2003-07-01 Takeda Chemical Industries, Ltd. β-amyloid protein production/secretion inhibitors
US6204288B1 (en) 1999-03-08 2001-03-20 The University Of Mississippi 1,2-dithiolane derivatives
US6653309B1 (en) 1999-04-26 2003-11-25 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme technical field of the invention
IL147308A0 (en) * 1999-06-30 2002-08-14 Tularik Inc Compounds for the modulation of pparγ activity and pharmaceutical compositions containing the same
CA2325358C (en) 1999-11-10 2005-08-02 Pfizer Products Inc. 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b
MXPA02006660A (es) * 2000-01-07 2002-12-13 Transform Pharmaceuticals Inc Formacion, identificacion y analisis de diversas formas solidas de alto rendimiento.
TW533656B (en) * 2000-04-07 2003-05-21 Mirae Corp Cooling control system of linear motor
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
EP1344525A4 (en) 2000-12-22 2005-05-25 Ishihara Sangyo Kaisha ANILINE DERIVATIVES OR ITS SALTS AND CYTOKINE PRODUCTION INHIBITORS CONTAINING THEM
GB2373725A (en) 2001-03-30 2002-10-02 Novartis Ag Use of a PPAR gamma agonist in the production of a medicament for the prevention or treatment of diseases associated with IL-10 production
US7223761B2 (en) * 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
AU2005221140A1 (en) * 2004-03-08 2005-09-22 Amgen Inc. Therapeutic modulation of PPAR (gamma) activity

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200995B1 (en) * 1998-01-29 2001-03-13 Tularik Inc. PPAR-γ modulators
US6583157B2 (en) * 1998-01-29 2003-06-24 Tularik Inc. Quinolinyl and benzothiazolyl modulators
US6770648B2 (en) * 1999-06-30 2004-08-03 Tularik Inc. Compounds for the modulation of PPARγ activity
US6653332B2 (en) * 2000-05-03 2003-11-25 Tularik Inc. Combination therapeutic compositions and method of use
WO2002000633A1 (en) * 2000-06-28 2002-01-03 Tularik Inc. Quinolinyl and benzothiazolyl ppar-gamma modulators

Also Published As

Publication number Publication date
KR101156277B1 (ko) 2012-07-05
CA2540536C (en) 2013-07-02
ATE546142T1 (de) 2012-03-15
JP2007507537A (ja) 2007-03-29
US20050143416A1 (en) 2005-06-30
BRPI0414957A (pt) 2006-11-07
US20070293536A1 (en) 2007-12-20
ZA200602669B (en) 2007-07-25
WO2005033074A3 (en) 2005-06-16
CN1886134A (zh) 2006-12-27
IL174728A0 (en) 2006-08-20
DK1677797T3 (da) 2012-06-04
EA200600701A1 (ru) 2006-10-27
NZ546783A (en) 2008-11-28
KR20060097121A (ko) 2006-09-13
WO2005033074A2 (en) 2005-04-14
EP1677797A4 (en) 2009-03-25
ES2386670T3 (es) 2012-08-24
US8003665B2 (en) 2011-08-23
JP5426813B2 (ja) 2014-02-26
AU2004278416B2 (en) 2010-04-15
IS8378A (is) 2006-03-27
NO333002B1 (no) 2013-02-11
US7223761B2 (en) 2007-05-29
EP1677797B1 (en) 2012-02-22
JP2012097090A (ja) 2012-05-24
EP1677797A2 (en) 2006-07-12
AU2004278416A1 (en) 2005-04-14
CA2540536A1 (en) 2005-04-14
MXPA06003313A (es) 2006-06-08
IL174728A (en) 2011-06-30
NO20061974L (no) 2006-07-03

Similar Documents

Publication Publication Date Title
EA013367B1 (ru) Соли и полиморфные формы эффективного антидиабетического соединения
DE69720429T9 (de) Heterocyclische verbindungen als antidiabetische mittel und für die behandlung von fettleibigkeit
TW201827405A (zh) 囊腫纖化症跨膜傳導調節蛋白調控劑、醫藥組合物、治療方法及製備該調控劑之方法
JPH1036348A (ja) ヘテロ環β−アドレナリン作働性アゴニスト
MXPA97002601A (en) Agonistasó-adrenergicos heterocicli
EA028869B1 (ru) Модуляторы рецептора андрогенов и их применение
JP4832897B2 (ja) エステル誘導体及びその医薬用途
JP7146159B2 (ja) プロブコール誘導体及びその調製方法と使用
ES2408961T3 (es) Derivados de amidas del ácido 3-trifluorometil-pirazin-2-carboxílico como agentes para aumentar el colesterol HDL.
KR102691700B1 (ko) 2-(5-(4-(2-모르폴리노에톡시)페닐)피리딘-2-일)-n-벤질아세트아미드의 고체 형태
TW202227390A (zh) 結晶型edg-2受體拮抗劑及製造方法
WO2022063333A1 (zh) 一种嘧啶甲酰胺类化合物及其应用
EP0837850A1 (en) 4-acylamino(halogeno) alkyl-quinoline derivatives, their preparation and their use as melatonin agonists
KR102514860B1 (ko) 5-ht7 세로토닌 수용체 활성 저해용 바이페닐 피롤리딘 및 바이페닐 다이하이드로이미다졸 유도체 및 이를 유효성분으로 포함하는 약학 조성물
TWI811901B (zh) 一種嘧啶甲醯胺類化合物及其應用
JPH0436151B2 (ja)
CN114702444B (zh) 一种具有抗多发性骨髓瘤作用的aha1抑制剂及其制备方法和应用
RU2394020C2 (ru) Кристаллический ингибитор ахат
KR20200102565A (ko) 피라졸로피리다진 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물
EA009023B1 (ru) Селективные модуляторы рецептора, активируемого пролифератором пероксисом
JP2000191664A (ja) 縮合ピリダジン誘導体、その製造法および用途
JPH06157467A (ja) ３−アザビシクロ［３．２．１］オクタン誘導体およびその用途

Legal Events

Date Code Title Description
NF4A Restoration of lapsed right to a eurasian patent

Designated state(s): AM AZ BY KZ MD TJ TM RU

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU

NF4A Restoration of lapsed right to a eurasian patent

Designated state(s): KG

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): KG